Bioidentical Hormones for Better Living and Patient Wellness

Improve your wellness with bioidentical hormones. Discover the benefits for patients seeking hormonal balance and well-being.

Abstract

In this educational post, I guide you through a practical, evidence-informed approach to hormone optimization, women’s health, and integrative strategies for mood, migraines, and metabolism—while highlighting when to collaborate with specialists. We explore bioidentical hormone sourcing and safety, perimenopause-to-menopause transitions, contraceptive considerations, transgender care referral pathways, lab interpretation for thyroid and sex hormones, progesterone strategies for anxiety and sleep, estrogen “trough” support for menstrual migraines, IUD considerations, and nutraceuticals that meaningfully move physiology. I also unpack the role of lifestyle biology—sleep, circadian timing, nutrition quality, and stress physiology—in shaping outcomes, and I show how integrative chiropractic care fits into a modern, team-based framework. Throughout, I share clinical observations from my practice and platforms and cite leading research so you can see how contemporary, evidence-based methods translate into everyday care.

Introduction: My integrative approach to hormones, mood, and metabolism

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In clinic and on the platforms where I teach and write, I aim to connect rigorous, modern evidence with hands-on, patient-centered care. Hormones do not exist in isolation from the musculoskeletal system, the gut, the brain, or the way we sleep and move. As a chiropractor and advanced practice clinician, I integrate structural assessment and manual therapies with functional medicine diagnostics, precise hormone replacement when indicated, and lifestyle interventions that rewire physiology.

This post distills key questions that often arise in practice and in clinician education settings—translated here as a clear, step-by-step guide. I present the latest findings from leading researchers using contemporary methods, while layering in the practical “how” from real-world cases I discuss on PushAsRx and on my professional channels. The throughline is simple: evidence-driven, individualized, and integrative.

Bioidentical hormones: what they are and where they come from

• Key concept: bioidentical hormones are structurally identical to human hormones. Most compounded estradiol, progesterone, and testosterone used today are synthesized from plant sterols.
• Source and chemistry:

• • Modern bioidentical hormones are typically synthesized from diosgenin-rich plant sterols extracted from wild yam (Dioscorea species) or from sitosterol in soy. While early manufacturing leaned heavily on soy, most USUSompounding supply lines now derive the starting sterol from yams. Through well-established organic chemistry steps, the plant sterol backbone is transformed into human-identical estradiol (E2), progesterone (P4), or testosterone (T) that the body recognizes and can metabolize via native hepatic and peripheral pathways (Sood et al., 2020).
  • Why “bioidentical” matters: receptor affinity and downstream gene transcription patterns with E2, P4, and T mirror endogenous signaling more closely than with certain synthetic analogs, potentially influencing metabolic, vascular, and neural effects (The Endocrine Society, 2019).

• Evidence snapshot:

• • Transdermal estradiol avoids first-pass hepatic induction of clotting factors compared with many oral ethinyl estradiol formulations, thereby reducing the risk of venous thromboembolism in appropriate candidates (NAMS, 2022; Vinogradova et al., 2019).
  • Micronized progesterone shows a more favorable profile for sleep and GABAergic calm relative to some synthetic progestins, with lower VTE signal when paired with transdermal E2 (de Villiers et al., 2020; NAMS, 2022).

• My clinical note:

• • In my practice, bioidentical preparations allow me to titrate to symptom relief while tracking labs and physiologic metrics. I anchor dosing to physiology, not to fixed recipes—respecting age, cycle status, comorbidities, and patient goals.

Integrative libido support layering topical therapies with pellets or systemic HRT.

• Clinical question: Can topical libido-supporting creams be layered over existing hormone pellets?

• • In many cases, yes. Compounded topical formulas for libido may include low-dose testosterone, combination androgen/estrogen blends, or non-hormonal vasodilators. Because transdermal genital-skin absorption engages local androgen receptors and increases genital blood flow via nitric oxide pathways, a well-designed cream can complement a stable systemic regimen, including pellets, without”stacking” systemic levels excessively (Kingsberg et al., 2019).
  • Why it works: local androgen signaling enhances clitoral and vaginal tissue responsiveness; augmented nitric oxide signaling improves arousal, lubrication, and sexual satisfaction.
  • Guardrails: measure serum total and free testosterone, SHBG, and DHT at baseline and follow-up; monitor for androgenic adverse effects (acne, hair changes, voice deepening). I prefer minimal effective dosing, targeted application, and periodic holidays to reassess need.

• Evidence anchor:

• • Testosterone therapy for hypoactive sexual desire disorder in postmenopausal women improves desire and satisfying sexual events at physiologic female ranges (Global Consensus Position Statement, 2019).
  • Localized topical strategies may minimize systemic excursions when carefully compounded and applied (NAMS, 2022).

• Integrative chiropractic fit:

• • Pelvic floor biomechanics, lumbar-pelvic alignment, and myofascial restriction can blunt sexual function. My integrative chiropractic evaluation often identifies sacroiliac joint mechanics, obturator internus tension, or diaphragmatic restriction that respond to manual therapy and targeted pelvic floor rehab, complementing biomedical libido interventions.

Contraception, perimenopause, and when to stop birth control pills

• Principle: “Birth control pills are for birth control.” If contraception is no longer needed, continuing combined oral contraceptives (COCs) solely for symptom control past the mid-40s requires a careful risk–benefit review.

• • Physiologic rationale: Ethinyl estradiol in many COCs increases hepatic synthesis of clotting factors and SHBG. Age, smoking status, migraine with aura, and cardiometabolic risks increase the baseline risk of venous thromboembolism or stroke (Curtis et al., 2016).
  • Clinical practice: For patients no longer needing contraception, I transition from COCs to individualized menopausal hormone therapy (MHT) when symptoms warrant, favoring transdermal estradiol with micronized progesterone where appropriate to reduce thrombotic risk (NAMS, 2022).

• Assessing menopausal status while on the pill:

• • Lab-based approach: Follicle-stimulating hormone (FSH) can be misleading on COCs. A pragmatic method is to pause COCs for approximately 3 weeks, bridge with barrier contraception, then measure FSH and estradiol. Persistently elevated FSH (e.g., ≥23–30 IU/L) off COCs is consistent with ovarian insufficiency/menopause (NICE, 2019).
  • Dosing while uncertain: If vasomotor symptoms are debilitating and the menopausal status is unclear, I may initiate a conservative “perimenopausal” estradiol dose (for example, transdermal E2 at lower microgram ranges) and titrate up based on symptom control and bleeding patterns, reassessing at 6–8 weeks.

• Why this approach:

• • It avoids under- or over-replacement during the transition and reduces risks tied to high ethinyl estradiol exposure in non-contraceptive users.

Transgender care scope, referral, and team-based pathways

• Clarity of scope: Transition-related hormone initiation and monitoring require specialized protocols, informed consent models, and psychosocial support. I collaborate with and refer to specialists who follow evidence-based standards (WPATH Standards of Care v8; Hembree et al., 2017).
• My role:

• • For transgender patients already stable on gender-affirming regimens, I can assist with general health, musculoskeletal care, lifestyle medicine, and coordination. However, de novo transitioning should be guided by dedicated teams (endocrinology, mental health, urology/gynecology).

• Resource guidance:

• • The Endocrine Society’s guidelines and WPATH provide detailed guidance on dosing, monitoring, and risk stratification that exceeds the scope of a general hormone optimization visit. This ensures safety, psychological support, and continuity.

Menstrual migraines and the estrogen “trough” strategy

• Mechanism: In many menstruators, migraine susceptibility increases with the rapid premenstrual drop in estradiol. This “estrogen withdrawal” can facilitate trigeminovascular activation, cortical spreading depression, and sensitization of meningeal nociceptors through CGRP and nitric oxide pathways (MacGregor, 2018).
• Targeted intervention:

• • Short-course, low-dose estradiol “bridging” around the late luteal phase buffers the trough and reduces attacks without disrupting ovulatory cycles. Practical options include very low-dose transdermal estradiol initiated a few days before menses and continued briefly into menstruation.

• Why it helps:

• • Smoothing the hormonal gradient dampens central and peripheral sensitization circuits linked to cyclic estrogen decline, often reducing attack frequency and severity by a clinically meaningful margin.

• Integrative chiropractic fit:

• • Cervicogenic contributions frequently amplify migraine load. Upper cervical joint dysfunction, suboccipital myofascial hypertonicity, and impaired diaphragmatic breathing can fuel nociceptive input. I combine hormone trough buffering with cervical stabilization, suboccipital release, and breathing mechanics to reduce migraine burden synergistically.

Progesterone for sleep and anxiety: tuning the GABAergic system

• Physiology:

• • Micronized progesterone metabolizes into neuroactive steroids such as allopregnanolone, which are potent positive allosteric modulators of the GABA-A receptor. This can promote sleep initiation, increase stage N2 sleep, and reduce nocturnal awakenings in selected patients (de Villiers et al., 2020).

• Clinical application:

• • Night-time micronized progesterone can improve sleep and perimenopausal anxiety. In younger patients with severe premenstrual anxiety, low-dose, short-course support may be considered carefully, with attention to cycle timing.

• Strategy:

• • Start low and monitor next-day sedation. Combine with sleep hygiene and circadian reinforcement.

• Pediatric and adolescent considerations:

• • For teens with dramatic hormonal fluctuations, I prioritize lifestyle physiology—sleep timing, screen curfews, nutrient density, and stress skills. My clinical experience aligns with research showing that late bedtimes and screen exposure suppress deep sleep and blunt nocturnal growth hormone (GH) pulses, reducing IGF-1 and compromising recovery and mood (Mirea et al., 2021). I avoid sedatives when possible; occasional off-label agents are used cautiously and short-term while the root cause is addressed.

Thyroid testing, timing, and assay selection

• Assays:

• • Liquid chromatography–tandem mass spectrometry (LC–MS/MS) improves specificity for steroid hormones and is valuable when immunoassay interference is suspected. For thyroid hormones, high-quality immunoassays are generally reliable, but interference can occur on both platforms under certain conditions (Janssen et al., 2021).

• Practical pearl:

• • Ask exactly when the patient took T3-containing thyroid medication relative to phlebotomy. Serum T3 peaks 2–4 hours post-dose; drawing immediately post-dose may show an apparently “high” T3 that reflects the peak rather than the trough. I document dosing time on the lab requisition and interpret in context.

• Why it matters:

• • Appropriate interpretation avoids unnecessary dose changes and iatrogenic hypo- or hyperthyroidism.

IUDs, progesterone exposure, and menopausal hormone therapy

• Levonorgestrel-releasing IUDs:

• • Deliver concentrated progestin intrauterine with minimal systemic levels relative to oral progestins. They are excellent for abnormal uterine bleeding and contraception and do not reliably alter FSH trajectories used for menopause determination (NICE, 2019).

• In menopause:

• • If an IUD is in situ at menopause and controlling bleeding, some patients prefer to leave it temporarily while adding systemic estradiol; additional progestogen is often still recommended to assure endometrial protection when systemic estrogen is used, as data are mixed on whether IUD alone provides sufficient endometrial protection for all doses of systemic estradiol (NAMS, 2022).

• Procedural considerations:

• • Removal can occasionally be challenging due to string retraction or embedment. Collaboration with gynecology ensures safe management.

Topical cosmetic estrogens and systemic exposure

• Issue:

• • Some cosmetic products abroad have contained topical estrogens. Theoretically, facial or widespread application of estradiol- or estriol-containing products can lead to systemic absorption, with increased risk if combined with other estrogen therapies.

• Clinical stance:

• • I advise patients to disclose all topical “cosmeceuticals.” Applying compounded estradiol to large surface areas (e.g., face) can meaningfully elevate serum estradiol due to thin skin and high vascularity. If facial application is desired for cosmetic purposes, preferring very low-dose estriol formulations and restricting the area can mitigate systemic impact, but I still monitor levels.

• Why it matters:

• • Unaccounted estrogen exposure confounds dose titration and can increase risk in estrogen-sensitive conditions.

Endometrial protection and the progesterone route

• Core principle:

• • When systemic estrogen is used in women with a uterus, adequate endometrial protection is essential. While vaginal progesterone can achieve high uterine tissue levels, currently available data do not define a universally protective dose across all systemic estradiol regimens and patient phenotypes (NAMS, 2022).

• My approach:

• • I prioritize oral micronized progesterone for well-established endometrial protection in most systemic estrogen users, especially at standard estradiol doses. When using vaginal routes, I align dosing with available evidence and monitor closely for bleeding or ultrasonographic changes.

Anxiety, PMS, and the gut-brain a:xis lifestyle first, meds last

• Clinical observation:

• • I often see patients on multiple psychotropics with persistent anxiety or depressive features linked to glycemic volatility, nutrient gaps, and dysbiosis. Addressing these can permit deprescribing.

• Physiology:

• • High glycemic loads and caffeine excess upregulate sympathetic output and destabilize HPA-axis tone; dysbiotic shifts can affect tryptophan metabolism and short-chain fatty acid production, influencing neuroinflammation and mood (Slykerman et al., 2022).

• Interventions:

• • Nutrition: prioritize protein-forward, fiber-rich meals; remove ultra-processed, sugar-laden beverages (think 40–60 g of sugar per drink); add magnesium glycinate or citrate when appropriate; consider omega-3s for neuroinflammation; and employ probiotics with evidence for mood support.
  • Sleep/circadian: strict dim-light hygiene, device curfew, consistent sleep/wake windows.
  • Movement: resistance and zone-2 aerobic exercise to enhance insulin sensitivity and BDNF.

• Why it works:

• • Stabilizing glucose and dampening sympathetic surges reduces limbic reactivity; improved sleep restores glymphatic clearance and neuroendocrine rhythms.

Testosterone, lipids, and cardiovascular nuance

• Perspective:

• • In women, physiologic-range testosterone replacement has not been shown to increase atherosclerotic risk when carefully monitored; HDL may vary, and triglycerides often normalize with improved insulin sensitivity and body composition (Global Consensus, 2019).

• Genetic hyperlipidemias:

• • Familial patterns can dominate lipid phenotypes. Coordination with cardiology is essential for patients with familial hypercholesterolemia or Lp(a) elevation; testosterone is not typically the driver.

• Monitoring:

• • I trend apoB, LDL-C, HDL-C, triglycerides, Lp(a) where relevant, and I examine body composition and fitness alongside lipids to interpret risk.

Injection technique and needle gauge for hormones

• Practical tip:

• • For subcutaneous or intramuscular hormone injections, needle gauge selection must balance viscosity and patient comfort. Thicker oils may require 27-gauge needles; however, many compounded estradiol or testosterone preparations flow through 28–30-gauge needles if dilution and temperature are appropriate. I favor the thinnest gauge that allows smooth delivery without excessive force, reducing tissue trauma.

When to co-manage with specialists

• Urology and gynecology:

• • Pelvic pain, complicated IUD issues, refractory urinary symptoms, or anatomic concerns benefit from specialist input. I maintain relationships with regional urologists and gynecologists and coordinate care to ensure a seamless patient experience.

• Oncology collaboration:

• • For patients with a history of hormone-sensitive cancers, I work closely with oncologists. Contemporary literature suggests that carefully individualized menopausal hormone therapy may be considered in select survivors after thorough risk assessment; however, oncologist oversight is crucial. I encourage sharing up-to-date, peer-reviewed evidence and using open-access repositories that collate the data for clinician–patient discussions (NAMS, 2022; Dew et al., 2021).

Integrative chiropractic care: the structural-biochemical interface

• Why structure matters in hormone care:

• • The autonomic and neuroendocrine systems are mechanosensitive. Cervical proprioception influences vestibular and limbic circuits; thoracic mobility affects respiratory mechanics and vagal tone; pelvic alignment and fascial tension impact pelvic organ function and sexual comfort. Targeted manual therapies can reduce nociceptive input, lower sympathetic overdrive, and create a physiologic milieu that enhances the effectiveness of hormonal therapies.

• My framework:
  • Assessment: regional interdependence from foot mechanics to the atlanto-occipital junction.
  • Interventions: high-velocity low-amplitude adjustments where indicated, soft tissue release, graded exposure exercise, breath training, and pelvic floor neuromuscular re-education.
  • Results:

• Migraine: adding cervical and thoracic manual therapy to estrogen-trough bridging reduces frequency and intensity in many patients in my clinic.
• Libido: pelvic floor coordination training and sacroiliac joint normalization often improve dyspareunia and arousal responsiveness alongside topical androgen therapy.
• Sleep/anxiety: thoracic mobility and diaphragmatic retraining improve CO2 tolerance and vagal tone, complementing the GABAergic effects of micronized progesterone.

Putting it all together, a phased, evidence-informed plan

• Phase 1: Clarify goals and safety

• • Define contraception needs, cancer history, thrombotic risks, and current symptom map. Gather baseline labs: CBC, CMP, lipid panel with apoB, TSH with free T4/T3 as indicated, estradiol, progesterone (timed to cycle if premenopausal), total/free testosterone with SHBG, FSH/LH, A1c, fasting insulin, vitamin D, ferritin, and CRP.

• Phase 2: Lifestyle physiology reset

• • Sleep schedule and light exposure; eliminate sugar-sweetened beverages; protein target ~1.2–1.6 g/kg/day as appropriate; magnesium repletion; omega-3 intake; walking after meals; strength training twice weekly and zone-2 cardio.

• Phase 3: Targeted hormonal support

• • Menstrual migraines: low-dose luteal estradiol bridge.
  • Perimenopause/menopause: transdermal E2 plus oral micronized P4; titrate.
  • Libido: topical, localized androgen/vasoactive cream with guardrails, layered over stable systemic therapy if indicated.
  • Thyroid: rationalize LT4/LT3 dosing based on kinetics and assay results.

• Phase 4: Structural integration

• • Chiropractic assessment and treatment plan synchronized with hormonal milestones.

• Phase 5: Reassessment and refinement

• • Recheck labs at 6–12 weeks after dose changes; repeat symptom inventories; adjust lifestyle programming; maintain open co-management with specialists.

Clinical observations from my practice

• From PushAsRx and my clinic channels, I consistently see:

• • Patients with refractory anxiety improve markedly when caffeine and high-sugar beverages are replaced with hydration and protein-forward meals, combined with magnesium and sleep repairs.
  • Menstrual migraine frequency drops with estradiol-trough buffering plus cervical/thoracic manual therapy and breathwork.
  • Libido responds best when biomechanics and pelvic floor function are corrected in parallel with localized androgen therapy rather than pharmacology alone.
  • Teens dramatically improve energy, mood, and growth markers when device curfews restore deep sleep, underscoring the non-negotiable link between circadian biology and endocrine health.

Why this matters is a modern, humane, and rigorous standard

• Precision without perfectionism:

• • Evidence evolves; the body changes across seasons of life. Our task is not to chase lab perfection but to support adaptive physiology.

• Integration over silos:

• • The strongest outcomes occur when structural, biochemical, and behavioral interventions work in concert—and when we humbly collaborate with specialists.

• Patient agency:

• • Shared decision-making empowers patients to weigh benefits and risks, from contraception choices to hormone routes and lifestyle pivots.

References

• Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., et al. (2016). U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recommendations and Reports, 65(3), 1–103. https://www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm
• de Villiers, T. J., Hall, J. E., Pinkerton, J. V., et al. (2020). Revised global consensus statement on menopausal hormone therapy. Climacteric, 23(5), 1–9. https://www.tandfonline.com/doi/full/10.1080/13697137.2020.1761491
• Dew, J. E., Khan, M., & Hickey, M. (2021). Menopausal hormone therapy after breast cancer. Maturitas, 151, 44–54. https://www.sciencedirect.com/science/article/pii/S0378512221001399
• Global Consensus Position Statement on the Use of Testosterone Therapy for Women. (2019). The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666. https://academic.oup.com/jcem/article/104/10/4660/5556103
• Hembree, W. C., Cohen-Kettenis, P., Gooren, L., et al. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. https://academic.oup.com/jcem/article/102/11/3869/4157558
• Janssen, M. J. W., et al. (2021). Analytical challenges in steroid and thyroid hormone measurement. Best Practice & Research Clinical Endocrinology & Metabolism, 35(5), 101546. https://www.sciencedirect.com/science/article/pii/S1521690X21000617
• Kingsberg, S. A., et al. (2019). A practical guide to female sexual desire disorders. The Female Patient. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821450/
• MacGregor, E. A. (2018). Migraine in women: The role of hormones and their impact on vascular diseases. The Journal of Headache and Pain, 19(1), 76. https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-018-0897-1
• North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
• (2019). Menopause: Diagnosis and management (NG23). https://www.nice.org.uk/guidance/ng23
• Slykerman, R. F., et al. (2022). Gut microbiome and mental health: Mechanisms and modulation. Nutrients, 14(21), 4446. https://www.mdpi.com/2072-6643/14/21/4446
• Sood, R., et al. (2020). Bioidentical hormones: Facts and realities. Mayo Clinic Proceedings, 95(12), 2798–2811. https://www.mayoclinicproceedings.org/article/S0025-6196(20)31079-9/fulltext
• Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2019). Use of hormone replacement therapy and risk of venous thromboembolism. BMJ, 364, k4810. https://www.bmj.com/content/364/bmj.k4810

Author and clinical platforms

• Clinical observations and patient-centered applications are discussed further on my platforms:

• • PushAsRx integrative performance and rehabilitation: https://pushasrx.com/
  • Professional profile and ongoing updates: https://www.linkedin.com/in/dralexjimenez/

SEO tags: bioidentical hormones, menopausal hormone therapy, perimenopause management, menstrual migraine estrogen, libido cream testosterone women, levonorgestrel IUD menopause, progesterone for sleep, micronized progesterone anxiety, thyroid T3 testing timing, LC-MS/MS hormones, integrative chiropractic care hormones, pelvic floor and libido, migraine manual therapy, gut-brain axis anxiety, contraceptive transition menopause, evidence-based hormone therapy